Innate Pharma SA (FR:IPH) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Innate Pharma SA has announced its selection for the 2024 ASH Annual Meeting, highlighting their progress with lacutamab and the SAR443579 asset, developed in collaboration with Sanofi. These advancements reflect Innate’s commitment to delivering new cancer treatments, particularly for lymphomas with high unmet needs. The company’s innovative approach and strategic partnerships position it as a significant player in the biotech sector.
For further insights into FR:IPH stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- ‘Stay Away,’ Says Hans Mosesmann About Intel Stock
- Canaccord Pounds the Table on Archer Aviation Stock
- ‘Don’t Let the Law of Large Numbers Scare You,’ Says Top Investor About Nvidia Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
